|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-23 in tumor tissues of pancreatic cancer patients was correlated with clinical stage. miR-425-5p and IL-23 may be involved in the pathological development of pancreatic cancer.
|
30944648 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A proinflammatory cytokine, interleukin 23 (IL-23), plays a role in tumor progression by inducing inflammation in the tumor microenvironment, although there is debate about its role in carcinogenesis.
|
23250909 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Batf-dependent IL-23R(+)IL-6(+)CD4(+) Th17 cells critically control IL-23 driven colitis-associated tumour formation and the progression of sporadic colon tumours.
|
25838550 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
During polyoma middle T (PyMT) induced tumor progression, levels of Th17 inducing cytokines TGF-β, IL-6, IL-23 were increased in PyMT/Tgfbr2(KO) tumors, which was associated with an increased number of Th17 cells.
|
22408746 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show that by itself a neutralizing monoclonal antibody (mAb) to IL-23 suppressed early experimental lung metastases in the B16F10 mouse model of melanoma and also modestly inhibited the subcutaneous growth of primary tumors.
|
21282337 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show, for the first time, that IL-23R is up-regulated in primary B-ALL cells, compared with normal early B lymphocytes, and that IL-23 dampens directly tumor growth in vitro and in vivo through the inhibition of tumor cell proliferation and induction of apoptosis.
|
20671120 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-12 and IL-23 also play a key role in immune responses to infections and tumors.
|
29704872 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-17 and IL-23p19, both uniquely M1 polarization markers, transiently increased in the tumor interstitial fluid.
|
29430789 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-39, a heterodimer of p19 and EBI3, is a newly found cytokine and its role in the pathogenesis of neoplasia has not been studied yet.
|
30506430 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, IL-23 increases the expression of the endothelial marker CD31 and proliferative marker Ki67 in tumors.
|
27956175 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In particular, we discuss the mechanism by which IL-23 promotes tumor growth and metastases and how the IL-12/IL-23 axis of inflammation can be targeted for cancer therapy.
|
28716888 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the tumor microenvironment, inflammatory cells and molecules influence almost every process; among them, interleukin-23 (IL-23) is a pro-inflammatory molecule that exhibits pro- or anti-tumor properties, but both activities remain poorly understood.
|
30483821 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin 23 (IL-23) affects tumor growth by regulating Th cells and plays a vital role in immunosuppression in tumor tissues.
|
21547355 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin 23 (IL-23) is an inflammatory cytokine which is reported to play an important role in tumor development in animal model.
|
23050001 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-23 (IL-23) is a conventional proinflammatory cytokine that plays a role in tumor progression by inducing inflammation in the tumor microenvironment.
|
26437444 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-23 (IL-23) is a general proinflammatory factor; and is involved in tumor-associated inflammation in gastric cancer (GC).
|
29574157 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intra-tumour MDSC infiltration and IL-23 concentration are increased in blood and tumour samples from patients with CRPC.
|
29950727 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment.
|
31616630 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro stimulation of monocytes with COL6 resulted in the production of IL-23, which may promote tumor development in an environment of IL-23-mediated lung inflammation, where tissue modeling occurs concurrently with excessive COL6 production.
|
25176343 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCAO mice showed overexpression of interleukin-6 (IL-6), IL-17, and IL-23, and increased positive protein expression of PTGS2, as well as expression of PTGS2, nuclear factor-κB (NF-κB), tumor suppressor region 1 (TSP-1) and Bcl-2-associated X protein (Bax), but underexpression of vascular endothelial growth factor (VEGF), S-phase kinase associated protein 2 (Skp2), and B-cell lymphoma 2 (Bcl-2).
|
31222746 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we verified that IL-23 could maintain the potential tumorigenic of OCSCs in vivo and mediate the self-renewal ability and the formation of tumor in OCSCs by activating the signal pathways of STAT3 and NF-κB.
|
27738346 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cyclin-dependent kinase inhibitors known as p15, p16, p18 and p19 have been suggested as candidates for tumor suppressor genes.
|
9639410 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The positive correlations between glutamine metabolism, IL-23 levels, and Treg responses are confirmed in both TCGA cohort and tumors from Shanghai ccRCC patients.
|
30293904 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data collectively suggest that expression of IL-21 and IL-23 in tumors can produce NK cell-dependent and -independent antitumor effects in an alpha beta T cell-defective condition, respectively.
|
14502230 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We assayed the capacity of tumor promoters to induce human T-cell leukemia/lymphoma virus (HTLV) structural proteins p19 and p24 from the HTLV genome-carrying adult T-cell leukemia (ATL) cell lines, MT-1 and KH-2Lo, and fresh ATL cells.
|
6090008 |
1984 |